Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced that its Xinxin Pharmaceutical Plant has received two Drug Registration Certificates from China’s National Medical Products Administration for Loxoprofen Sodium Patches in 14 cm × 10 cm (100 mg) and 7 cm × 10 cm (50 mg) formats.

The patches, registered as Class 4 chemical drugs, are deemed to have passed China’s quality and efficacy consistency evaluation. The approvals, valid until Sep, 28 2031, allow commercial manufacture by Hunan Pagran Pharmaceutical Co., Ltd., with production to start once Good Manufacturing Practice requirements are met.

The company said the registrations are not expected to materially affect near-term financial performance. It cautioned that factors such as national policies and market conditions could influence the timing and scale of production and sales.

Loxoprofen Sodium Patches employ hot-melt patch technology as an upgraded form of Loxoprofen cataplasms and are indicated for anti-inflammatory and analgesic treatment of osteoarthritis, muscle pain, and trauma-related swelling or pain. Industry data cited by the company show that China’s three main terminal markets recorded sales of about RMB 920 million for Loxoprofen Sodium Patches in 2025, with the segment growing rapidly.

The approval marks a further step in the group’s strategy to expand its transdermal drug-delivery portfolio and develop additional modern patch products across chemical drugs, traditional medicine and healthcare categories.